SAR-260301
- Generic Name
- SAR-260301
A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2015-04-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 75
- Registration Number
- NCT01673737
- Locations
- 🇺🇸
Investigational Site Number 840001, Boston, Massachusetts, United States
🇺🇸Investigational Site Number 840002, Houston, Texas, United States
🇺🇸Investigational Site Number 840101, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath